Format

Send to

Choose Destination
Best Pract Res Clin Obstet Gynaecol. 2017 Apr;40:105-110. doi: 10.1016/j.bpobgyn.2016.12.002. Epub 2016 Dec 18.

The history and use of the progesterone receptor modulator ulipristal acetate for heavy menstrual bleeding with uterine fibroids.

Author information

1
University Pierre et Marie Curie, Hospital saint Antoine, 75012, Paris, France; Department of Ob Gyn, Hospital Foch, 92150, Suresnes, France. Electronic address: phbouchard1@me.com.
2
University Pierre et Marie Curie, Hospital saint Antoine, 75012, Paris, France; Department of Ob Gyn, Hospital Tenon, 75020, Paris, France.

Abstract

Progesterone receptor modulators (PRM) or selective progesterone receptor modulators have two remarkable effects in treated women. They considerably suppress endometrial bleeding by incompletely understood mechanisms, and when administered in women with symptomatic fibroids, they produce a significant and potentially long-term decrease in fibroid volume. The crucial advantage of this therapy lies with the absence of suppression of ovarian oestrogen secretion, which is in contrast to GnRH agonists. Long-term treatments have proven to be useful, especially in women approaching the menopausal transition. However, their use is associated with endometrial modifications called PRM-associated endometrial changes (PAECs). Although these abnormalities are now described as benign, the treatment is best administered in an intermittent manner where the PAECs rapidly disappear, while the beneficial effects on fibroid size and uterine bleeding are maintained or even improved in the long term.

KEYWORDS:

PRM-associated endometrial changes (PAECs); fibroids; progesterone receptor modulators (PRM); selective progesterone receptor modulators; uterine bleeding

PMID:
28169130
DOI:
10.1016/j.bpobgyn.2016.12.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center